• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by FSD Pharma Inc.

    6/28/24 5:01:24 PM ET
    $HUGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HUGE alert in real time by email
    6-K 1 fsd_6k.htm FORM 6-K fsd_6k.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of: June 2024

     

    Commission File Number: 001-39152

     

    FSD PHARMA INC.

    (Translation of registrant’s name into English)

     

    199 Bay St., Suite 4000

    Toronto, Ontario M5L 1A9, Canada

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒   Form 40-F ☐

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    FSD Pharma Inc.

    (Registrant)

     

     

     

     

     

    Date: June 28, 2024

    By:

    /s/ Nathan Coyle

     

     

     

    Nathan Coyle, Chief Financial Officer

     

     

     

    2

     

     

    EXHIBIT INDEX

     

    Exhibit

     

    Description

     

     

     

    99.1

     

    Press Release

     

     

    3

     

    Get the next $HUGE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HUGE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HUGE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario

      TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced that the reconsideration motion by Dr. Raza Bokhari at the Court of Appeal for Ontario was dismissed entirely in favour of Quantum BioPharma. Dr. Raza Bokhari, current CEO of Medicus Pharma, Ltd., was CEO of FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) now Qu

      4/14/25 7:30:00 AM ET
      $HUGE
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quantum Biopharma in Court With Dr. Raza Bokhari on January 24, 2025 Seeking a Court Order to Declare Him to Be a Vexatious Litigant and Other Litigation Updates

      Awards in favour of Quantum BioPharma Total Approximately $3 Million TORONTO, ON / ACCESS Newswire / January 17, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced that it will be back in the Ontario Superior Court of Justice on January 24, 2025. Quantum BioPharma is seeking a Court Order declaring Dr. Raza Bokhari, current CEO of Medicus Pharma,

      1/17/25 7:30:00 AM ET
      $HUGE
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation

      TORONTO, ON / ACCESSWIRE / November 25, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) (the "Company") formerly named FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE) is pleased to follow up on recent events concerning the complaint filed by the Company in the United States courts, that alleges that CIBC World Markets, RBC Dominion Securities and others (the "Defendants") engaged in market manipulation in the share price of the Company. The Company, as well as its shareholders, have suffered financial and emotional losses resulting from this alleged manipulation. We are determined to right this wrong by the Defendants and reverse the Company losses and claim punitive damages to the e

      11/25/24 7:00:00 AM ET
      $HUGE
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HUGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by FSD Pharma Inc. (Amendment)

      SC 13D/A - FSD Pharma Inc. (0001771885) (Subject)

      4/11/22 10:01:53 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by FSD Pharma Inc.

      SC 13D - FSD Pharma Inc. (0001771885) (Subject)

      3/31/21 9:52:01 PM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed

      SC 13D/A - FSD Pharma Inc. (0001771885) (Subject)

      2/22/21 11:35:38 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HUGE
    Leadership Updates

    Live Leadership Updates

    See more
    • Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation

      TORONTO, ON / ACCESSWIRE / November 25, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) (the "Company") formerly named FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE) is pleased to follow up on recent events concerning the complaint filed by the Company in the United States courts, that alleges that CIBC World Markets, RBC Dominion Securities and others (the "Defendants") engaged in market manipulation in the share price of the Company. The Company, as well as its shareholders, have suffered financial and emotional losses resulting from this alleged manipulation. We are determined to right this wrong by the Defendants and reverse the Company losses and claim punitive damages to the e

      11/25/24 7:00:00 AM ET
      $HUGE
      $QNTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates

      TORONTO, ON / ACCESSWIRE / January 29, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to announce the appointment of Dr. Sanjiv Chopra to its board of directors. Dr. Chopra will be replacing Nitin Kaushal, who has resigned from his position on the board. FSD Pharma thanks Mr. Kaushal for his contribution and wishes him well on his future endeavours.Dr. Sanjiv ChopraDr. Sanjiv Chopra, MD, is Professor of Medicine and served as Faculty Dean for Continuing Medical Education at Harvard Medical School for 12 years. He serves as a Marshall W

      1/29/24 4:30:00 PM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FSD Pharma Files Supplement to Management Information Circular in Connection with Special Meeting to be Held on November 20, 2023

      TORONTO, ON / ACCESSWIRE / November 15, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions,is pleased to announce that it has provided certain additional disclosure, by way of a Supplement dated November 15, 2023 (the "Supplement") to its Management Information Circular dated October 20, 2023 (the "Circular"), relating to certain restrictions on resale that will apply to the Celly Nu Shares that will be distributed to the FSD Pharma Securityholders. Capitalized terms not defined in this news release have the meanings assigned in the Circular.FSD Phar

      11/15/23 9:00:00 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HUGE
    Financials

    Live finance-specific insights

    See more
    • Goldman Small Cap Research Publishes New Research Report on FSD Pharma, Inc.

      BALTIMORE, MD / ACCESSWIRE / November 24, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on FSD Pharma, Inc. (NASDAQ:HUGE)(CSE:HUGE), an innovative biopharmaceutical firm with one product slated for commercialization in 1Q24 and a unique treatment for MS preparing a Phase II clinical trial for 2H24 The Goldman report carries a price target. To view the new research report, along with disclosures and disclaimers, or to download the report in its entirety, please visit https://bit.ly/3Rer5Av.FSD Pharma is a biopharmaceutical company building a portfolio of innovative

      11/24/23 7:55:00 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FSD Pharma Inc. Securityholders Approve Plan of Arrangement with Celly Nutrition Corp.

      TORONTO, ON / ACCESSWIRE / November 21, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that the FSD Pharma Securityholders (defined below) have approved the previously-announced plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Arrangement") pursuant to which common shares in the capital of Celly Nutrition Corp. ("Celly Nu"), will be distributed to the holders of class A multiple voting shares ("Class A Shares"), class B subordinate voting shares ("Class B Shares"), and holders of warra

      11/21/23 8:45:00 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FSD Pharma Announces Distribution Date for Distribution of Celly Shares Pursuant to Plan of Arrangement

      TORONTO, ON / ACCESSWIRE / November 17, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that, further to its press release dated November 7, 2023, that its distribution date for the contemplated plan of arrangement (the "Arrangement") is November 29, 2023 (the "Distribution Date"). Subject to the satisfaction of all applicable closing conditions of the Arrangement, common shares in the capital of Celly Nutrition Corp. ("Celly Nu Shares") will be distributed to FSD Pharma Securityholders (as defined below) of record as of No

      11/17/23 8:00:00 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HUGE
    SEC Filings

    See more
    • SEC Form 6-K filed by FSD Pharma Inc.

      6-K - FSD Pharma Inc. (0001771885) (Filer)

      8/15/24 7:07:30 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 6-K/A filed by FSD Pharma Inc.

      6-K/A - FSD Pharma Inc. (0001771885) (Filer)

      8/14/24 6:15:16 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by FSD Pharma Inc.

      6-K - FSD Pharma Inc. (0001771885) (Filer)

      8/14/24 6:13:53 AM ET
      $HUGE
      Biotechnology: Pharmaceutical Preparations
      Health Care